Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K33/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
2.WO/2022/126127IODINE DELIVERY COMPOUNDS
WO 16.06.2022
Int.Class A61K 33/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
18Iodine; Compounds thereof
Appl.No PCT/US2021/072845 Applicant IOCURE, INC. Inventor FARB, Mark Daniel
Disclosed herein are methods and compositions for manufacturing pharmaceutical compositions and treating and ameliorating pathological conditions, using carriers conjugated to iodine-containing compounds; and therapeutic mixtures including iodine-containing compounds
3.WO/2021/181372AMORPHOUS CALCIUM CARBONATE FOR TREATMENT OF ACIDOSIS
WO 16.09.2021
Int.Class A61K 33/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
06Aluminium, calcium or magnesium; Compounds thereof
10Carbonates; Bicarbonates
Appl.No PCT/IL2021/050103 Applicant AMORPHICAL LTD. Inventor BEN, Yossi
The preset invention is directed to ACC particles stabilized by at least one stabilizing agent, a pharmaceutical composition including same, and methods of using same, such as for treating or preventing an acidosis-related disease or condition in a subject in need thereof.
4.WO/2021/216562ZINC FOR TREATING COVID-19
WO 28.10.2021
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No PCT/US2021/028174 Applicant FINZI, Eric Inventor FINZI, Eric
Methods are provided for treating a SARS-CoV-2 infection in a subject. These methods include selecting a subject with a SARS-CoV-2 infection; and administering to the subject with the SARS-CoV-2 infection an effective amount of elemental zinc, such as in the form of a zinc salt, thereby treating the SARS-CoV-2 infection in the subject. The subject can have long COVID.
5.WO/2022/119914METHODS OF INHIBITING RNA PROOFREADING AND THERAPEUTIC APPLICATIONS THEREOF
WO 09.06.2022
Int.Class A61K 33/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
14Alkali metal chlorides; Alkaline earth metal chlorides
Appl.No PCT/US2021/061390 Applicant SCHMIER, Brad Inventor SCHMIER, Brad
The invention relates to the use of a combination of a lithium composition with at least one inhibitor of an RNA-dependent RNA polymerase in the treatment of an RNA virus, wherein the RNA virus encodes a 3' to 5' exonuclease.
6.WO/2021/212183PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
WO 28.10.2021
Int.Class A61K 31/4706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
Appl.No PCT/AU2021/050369 Applicant CENTRE FOR DIGESTIVE DISEASES PTY LIMITED Inventor BORODY, Thomas Julius
Provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma "puffer-like" device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Said drug combinations include various combinations of antivirals, antiparasitics, antibacterials, and adjunct therapeutics, including at least one of Hydroxychloroquine, Chloroquine, Oseltamivir, Lopinavir, Ritonavir, Ribavirin, Favipiravir, Remdesivir, Azithromycin, Ivermectin, Doxycycline, and Opaganib or combinations thereof. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza vims, respiratory syncytial vims, picornavims, parainfluenza vims, adenovims, rhinovims, human metapneumovims, hantavimses, enterovims, a coronavims infection, or a COVID-19 or a 2019-nCoV (SARS-CoV-2) infection, or an infection caused by a vims in the subfamily Orthocoronavirinae, or a vims in the family Coronaviridae, or a vims in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a dmg or dmgs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
7.20210330635THERAPEUTIC COMPOSITIONS, PRODUCTS OF MANUFACTURE AND METHODS FOR AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
US 28.10.2021
Int.Class A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
Appl.No 17371036 Applicant CENTRE FOR DIGESTIVE DISEASES Inventor Thomas Julius BORODY

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™) and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

8.20210244705THERAPEUTIC COMPOSITIONS, PRODUCTS OF MANUFACTURE AND METHODS FOR AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
US 12.08.2021
Int.Class A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
Appl.No 17116942 Applicant CENTRE FOR DIGESTIVE DISEASES Inventor Thomas Julius BORODY

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™) and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

9.WO/2021/155443PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
WO 12.08.2021
Int.Class A61K 31/7048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Appl.No PCT/AU2021/050096 Applicant TOPELIA AUSTRALIA PTY LTD Inventor BORODY, Thomas Julius
Therapeutic agents, combination therapies, and methods for the treatment of coronavirus infections and associated diseases, particularly COVID-19, are provided. The provided therapeutics include oseltamivir, lopinavir, ritonavir, chloroquine or hydroxychloroquine, azithromycin, clarithromycin, doxycycline, ivermectin, and combinations thereof.
10.20220047571COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTION
US 17.02.2022
Int.Class A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Appl.No 17402419 Applicant Texas Southern University Inventor Omonike A. Olaleye

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.